Rene Russo - 22 Dec 2021 Form 4/A - Amendment Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
CEO AND PRESIDENT, Director
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
22 Dec 2021
Net transactions value
$0
Form type
4/A - Amendment
Filing time
04 Jan 2022, 16:32:35 UTC
Date Of Original Report
23 Dec 2021
Previous filing
21 Oct 2021
Next filing
24 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 22 Dec 2021 Common Stock 100,000 $13.83 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was granted on December 22, 2021 and shall vest on January 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until December 1, 2025.
F2 On December 23, 2021, the reporting person filed a Form 4 that inadvertently reported that the stock option shall continue to vest until December 1, 2026. This amendment is being filed solely to correct such date to December 1, 2025, as set forth in footnote 1.